Ghulam Mehdi Dar
Research Subjects
Ghulam Mehdi Dar has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Bhawna Mahajan
Central Molecular Laboratory, Govind Ballabh Pant Institute of Postgraduate Medical Education and Research (GIPMER), New Delhi, India
6 shared publicationsAbhay Kumar Sharma
Central Molecular Laboratory, Govind Ballabh Pant Institute of Postgraduate Medical Education and Research (GIPMER), New Delhi, India
5 shared publicationsArun Kumar
Central Molecular Laboratory, Govind Ballabh Pant Institute of Postgraduate Medical Education and Research (GIPMER), New Delhi, India
5 shared publicationsAsgar Ali
Central Molecular Laboratory, Govind Ballabh Pant Institute of Postgraduate Medical Education and Research (GIPMER), New Delhi, India
5 shared publicationsEjaj Ahmad
Central Molecular Laboratory, Govind Ballabh Pant Institute of Postgraduate Medical Education and Research (GIPMER), New Delhi, India
5 shared publicationsApurva
4 shared publications
Latest Publications
- 16 July 2026
- Published by Springer Nature in Nature Reviews Cardiology
- Vol. 23 (10) , 685
YAP at the heart of cardiac regeneration
- 16 July 2026
- Published by Springer Nature in Nature Reviews Cardiology
- Vol. 23 (10) , 685
YAP at the heart of cardiac regeneration
- 25 September 2023
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 19 (12) , 688
Sex differences in cardiometabolic health
- 25 September 2023
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 19 (12) , 688
Sex differences in cardiometabolic health
- 27 December 2022
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (1) , 441-465
Implication of gut microbes and its metabolites in colorectal cancer
Background Colorectal cancer (CRC) is the third most common cancer with a significant impact on loss of life. In 2020, nearly 1.9 million new cases and over 9,35,000 deaths were reported. Numerous microbes that are abundant in the human gut benefit host physiology in many ways. Although the underlying mechanism is still unknown, their association appears to be crucial in the beginning and progression of CRC. Summary Diet has a significant impact on the microbial composition and may increase the chance of getting CRC. Increasing evidence points to the gut microbiota as the primary initiator of colonic inflammation, which is connected to the development of colonic tumors. However, it is unclear how the microbiota contributes to the development of CRCs. Patients with CRC have been found to have dysbiosis of the gut microbiota, which can be identified by a decline in commensal bacterial species, such as those that produce butyrate, and a concurrent increase in harmful bacterial populations, such as opportunistic pathogens that produce pro-inflammatory cytokines. We believe that using probiotics or altering the gut microbiota will likely be effective tools in the fight against CRC treatment. Purpose In this review, we revisited the association between gut microbiota and colorectal cancer whether cause or effect. The various factors which influence gut microbiome in patients with CRC and possible mechanism in relation with development of CRC. Conclusion The clinical significance of the intestinal microbiota may aid in the prevention and management of CRC. Graphical abstract
- 27 December 2022
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (1) , 441-465
Implication of gut microbes and its metabolites in colorectal cancer
Background Colorectal cancer (CRC) is the third most common cancer with a significant impact on loss of life. In 2020, nearly 1.9 million new cases and over 9,35,000 deaths were reported. Numerous microbes that are abundant in the human gut benefit host physiology in many ways. Although the underlying mechanism is still unknown, their association appears to be crucial in the beginning and progression of CRC. Summary Diet has a significant impact on the microbial composition and may increase the chance of getting CRC. Increasing evidence points to the gut microbiota as the primary initiator of colonic inflammation, which is connected to the development of colonic tumors. However, it is unclear how the microbiota contributes to the development of CRCs. Patients with CRC have been found to have dysbiosis of the gut microbiota, which can be identified by a decline in commensal bacterial species, such as those that produce butyrate, and a concurrent increase in harmful bacterial populations, such as opportunistic pathogens that produce pro-inflammatory cytokines. We believe that using probiotics or altering the gut microbiota will likely be effective tools in the fight against CRC treatment. Purpose In this review, we revisited the association between gut microbiota and colorectal cancer whether cause or effect. The various factors which influence gut microbiome in patients with CRC and possible mechanism in relation with development of CRC. Conclusion The clinical significance of the intestinal microbiota may aid in the prevention and management of CRC. Graphical abstract
- 17 October 2022
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 180, 103850
A non-invasive miRNA-based approach in early diagnosis and therapeutics of oral cancer
- 17 October 2022
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 180, 103850
A non-invasive miRNA-based approach in early diagnosis and therapeutics of oral cancer
- 13 October 2022
- Published by Elsevier in Clinica Chimica Acta
- Vol. 537, 60-73
Molecular approaches in cancer
- 13 October 2022
- Published by Elsevier in Clinica Chimica Acta
- Vol. 537, 60-73
Molecular approaches in cancer
- 27 July 2022
- Published by Elsevier in Cellular Signalling
- Vol. 99, 110413
Diagnostic and prognostic biomarkers in colorectal cancer and the potential role of exosomes in drug delivery
- 27 July 2022
- Published by Elsevier in Cellular Signalling
- Vol. 99, 110413
Diagnostic and prognostic biomarkers in colorectal cancer and the potential role of exosomes in drug delivery
- 4 June 2022
- Published by Elsevier in Clinica Chimica Acta
- Vol. 532, 95-114
Molecular markers in cancer
- 4 June 2022
- Published by Elsevier in Clinica Chimica Acta
- Vol. 532, 95-114
Molecular markers in cancer
- 8 April 2022
- Published by Elsevier in Clinica Chimica Acta
- Vol. 531, 168-176
Teerakanchana’s equation transcends over 12 other LDL-C quantification formulae in the North Indian population
- 8 April 2022
- Published by Elsevier in Clinica Chimica Acta
- Vol. 531, 168-176
Teerakanchana’s equation transcends over 12 other LDL-C quantification formulae in the North Indian population